Veradigm (MDRX) Competitors $10.51 +0.07 (+0.67%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrends MDRX vs. NXGN, SLP, OMCL, HSTM, TLS, CRTX, AGYS, NTCT, VRNT, and DMRCShould you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include NextGen Healthcare (NXGN), Simulations Plus (SLP), Omnicell (OMCL), HealthStream (HSTM), Telos (TLS), Cortexyme (CRTX), Agilysys (AGYS), NetScout Systems (NTCT), Verint Systems (VRNT), and Digimarc (DMRC). Veradigm vs. NextGen Healthcare Simulations Plus Omnicell HealthStream Telos Cortexyme Agilysys NetScout Systems Verint Systems Digimarc Veradigm (NASDAQ:MDRX) and NextGen Healthcare (NASDAQ:NXGN) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment. Which has higher valuation and earnings, MDRX or NXGN? Veradigm has higher revenue and earnings than NextGen Healthcare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeradigm$1.50B0.75$134.44MN/AN/ANextGen Healthcare$653.17M2.46-$2.65M-$0.10-239.38 Is MDRX or NXGN more profitable? Veradigm has a net margin of 0.00% compared to NextGen Healthcare's net margin of -0.89%. NextGen Healthcare's return on equity of 11.37% beat Veradigm's return on equity.Company Net Margins Return on Equity Return on Assets VeradigmN/A N/A N/A NextGen Healthcare -0.89%11.37%5.38% Which has more risk & volatility, MDRX or NXGN? Veradigm has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, NextGen Healthcare has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Do analysts rate MDRX or NXGN? Veradigm currently has a consensus price target of $11.75, indicating a potential upside of 11.80%. Given Veradigm's stronger consensus rating and higher probable upside, equities research analysts clearly believe Veradigm is more favorable than NextGen Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50NextGen Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MDRX or NXGN? In the previous week, Veradigm had 4 more articles in the media than NextGen Healthcare. MarketBeat recorded 4 mentions for Veradigm and 0 mentions for NextGen Healthcare. NextGen Healthcare's average media sentiment score of 0.52 beat Veradigm's score of 0.00 indicating that NextGen Healthcare is being referred to more favorably in the news media. Company Overall Sentiment Veradigm Neutral NextGen Healthcare Positive Does the MarketBeat Community favor MDRX or NXGN? Veradigm received 486 more outperform votes than NextGen Healthcare when rated by MarketBeat users. Likewise, 58.90% of users gave Veradigm an outperform vote while only 47.04% of users gave NextGen Healthcare an outperform vote. CompanyUnderperformOutperformVeradigmOutperform Votes62958.90% Underperform Votes43941.10% NextGen HealthcareOutperform Votes14347.04% Underperform Votes16152.96% Do institutionals & insiders hold more shares of MDRX or NXGN? 76.7% of NextGen Healthcare shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 4.6% of NextGen Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryVeradigm beats NextGen Healthcare on 9 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Veradigm News Delivered to You Automatically Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDRX vs. The Competition Export to ExcelMetricVeradigmComputer integrated systems design IndustryBusiness SectorNASDAQ ExchangeMarket Cap$1.13B$3.90B$6.92B$8.82BDividend YieldN/A1.82%2.92%4.07%P/E RatioN/A16.0745.6017.66Price / Sales0.7515.02203.5874.22Price / CashN/A21.8124.3332.53Price / BookN/A18.295.084.68Net Income$134.44M$31.32M$121.19M$226.08M7 Day Performance-5.74%-5.13%-1.13%-2.03%1 Month Performance16.13%2.92%8.15%0.07%1 Year Performance-15.92%13.90%29.53%24.61% Veradigm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDRXVeradigm1.2489 of 5 stars$10.51+0.7%$11.75+11.8%-15.9%$1.13B$1.50B0.008,000Gap UpNXGNNextGen HealthcareN/A$23.94flatN/AN/A$1.61B$653.17M-239.382,783Analyst ForecastSLPSimulations Plus4.3093 of 5 stars$27.58-0.1%$51.40+86.4%-28.7%$553.53M$70.01M56.29192OMCLOmnicell3.1224 of 5 stars$41.82-1.4%$50.83+21.6%+26.7%$1.94B$1.15B-107.233,650Analyst RevisionHigh Trading VolumeHSTMHealthStream4.0314 of 5 stars$30.00-4.2%$31.50+5.0%+22.8%$912.60M$279.06M48.151,092TLSTelos3.3439 of 5 stars$3.20+1.6%$4.80+50.0%-17.3%$231.62M$145.38M0.00850CRTXCortexymeN/A$1.84+4.0%N/A+101.1%$55.48MN/A-0.6255AGYSAgilysys3.0124 of 5 stars$124.80-0.8%$134.80+8.0%+40.4%$3.49B$237.46M35.831,900Positive NewsNTCTNetScout Systems1.9845 of 5 stars$21.25+0.4%$22.00+3.5%+2.8%$1.52B$829.46M0.002,296Positive NewsVRNTVerint Systems4.8117 of 5 stars$23.50+0.9%$34.67+47.5%+0.1%$1.46B$910.39M34.763,700News CoveragePositive NewsDMRCDigimarc0.633 of 5 stars$32.92+5.0%$34.00+3.3%-2.6%$705.15M$34.85M0.00248 Related Companies and Tools Related Companies NextGen Healthcare Competitors Simulations Plus Competitors Omnicell Competitors HealthStream Competitors Telos Competitors Cortexyme Competitors Agilysys Competitors NetScout Systems Competitors Verint Systems Competitors Digimarc Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MDRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veradigm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
